This site is intended for U.S. residents only.

Learn about treatment with KYPROLIS® (carfilzomib)

Here you can find information about the dosing, administration, and treatment schedule with KYPROLIS. You can also access a tracker that can help you prepare for your KYPROLIS treatment. Talk with your doctor about the best treatment plan for you.

How will KYPROLIS be given?

Your doctor may prescribe KYPROLIS as part of your treatment plan to treat your relapsed multiple myeloma. KYPROLIS is given as an infusion in a doctor's office, a clinic, or a hospital. That means that you'll receive the medicine through an IV, directly into a vein. Click below to learn more about the 3 ways KYPROLIS may be given:

KYPROLIS + Rd (KYPROLIS + lenalidomide + dexamethasone) +

Graphic representing a 10-minute IV infusion. KYPROLIS is given as an infusion in your doctor’s office, a clinic, or a hospital. That means you will receive KYPROLIS through an IV, directly into a vein. Lenalidomide is taken as a pill, and dexamethasone can be infused or taken as a pill.







KYPROLIS is given on a schedule of 4 weeks. This 4-week schedule is called a treatment cycle. See the calendars for the correct treatment days. The calendars also show you what your treatment schedule might be.

Cycles 1-12

On Weeks 1-3, you should receive:

  • Dexamethasone on the first day, 30 minutes to 4 hours before you receive your infusion of KYPROLIS
  • KYPROLIS for 2 days in a row. Each infusion of KYPROLIS should last 10 minutes*
  • Lenalidomide once daily on Days 1-21
A calendar format shows the treatment schedule for Cycles 1-12 for KYPROLIS with lenalidomide and dexamethasone
Week 4
  • You should not have an infusion of KYPROLIS
  • You should receive dexamethasone on Day 22
Cycles 13-18
  • These cycles will be almost the same as Cycles 1-12. The only difference is that you will receive KYPROLIS only on Weeks 1 and 3 of your treatment cycle
  • Your doctor should stop your treatment with KYPROLIS after Cycle 18, or it may be stopped earlier if you experience side effects that cannot be managed
A calendar format shows the treatment schedule for Cycles 13-18 for KYPROLIS with lenalidomide and dexamethasone

You can keep track of your own KYPROLIS treatment schedule here.

*Your doctor should give you a lower dose on Days 1 and 2 of your first treatment cycle. If you tolerate that dose, your doctor may increase the dose of your other infusions of KYPROLIS. Your doctor will determine the right dose for you.

Discover how Amgen Assist 360™ can help you find resources most important to you.
Call 888-4ASSIST (888-427-7478) Monday through Friday, 9 am to 8 pm Eastern Time.

KYPROLIS + d (KYPROLIS + dexamethasone) +

Graphic representing a 30-minute IV infusion. KYPROLIS is given as an infusion in your doctor’s office, a clinic, or a hospital. That means you will receive KYPROLIS through an IV, directly into a vein. Dexamethasone can be infused or taken as a pill.







KYPROLIS is given on a schedule of 4 weeks. This 4-week schedule is called a treatment cycle. Look at the calendar to see what your treatment schedule might be.

Weeks 1, 2, and 3
  • Each week, for 2 days in a row, you should receive dexamethasone
  • Then, 30 minutes to 4 hours later, you should receive your infusion of KYPROLIS
  • Your infusion of KYPROLIS should last 30 minutes*
Week 4
  • You should not have an infusion of KYPROLIS
  • You should receive dexamethasone 2 days in a row, on the same days of the week as your infusion schedule
A calendar format shows the treatment schedule for KYPROLIS with dexamethasone

You can keep track of your KYPROLIS treatment schedule here.

*Your doctor should give you a lower dose on Days 1 and 2 of your first treatment cycle. If you tolerate that dose, your doctor may increase the dose of your other infusions of KYPROLIS. Your doctor will determine the right dose for you.

Discover how Amgen Assist 360™ can help you find resources most important to you.
Call 888-4ASSIST (888-427-7478) Monday through Friday, 9 am to 8 pm Eastern Time.

KYPROLIS single-agent +

Graphic representing a 30-minute or 10-minute IV infusion. KYPROLIS as a single agent (called monotherapy*) is given as an infusion in your doctor’s office, a clinic, or a hospital. That means you will receive KYPROLIS through an IV, directly into a vein.







KYPROLIS is given on a schedule of 4 weeks. This 4-week schedule is called a treatment cycle. Look at the calendars to see what your treatment schedule might be.

Cycles 1-12

Weeks 1, 2, and 3

  • KYPROLIS for 2 days in a row each week*
  • You should receive dexamethasone 30 minutes to 4 hours before each KYPROLIS infusion in Cycle 1, and as needed thereafter
A calendar format shows the treatment schedule for KYPROLIS single-agent
Week 4
  • You should not have an infusion of KYPROLIS
Cycles 13+
  • These cycles will be almost the same as Cycles 1-12
  • The only difference is that you should receive KYPROLIS only on Weeks 1 and 3 of your treatment cycle
A calendar format shows the treatment schedule for KYPROLIS single-agent

You can keep track of your own KYPROLIS treatment schedule here.

*Your doctor should give you a lower dose on Days 1 and 2 of your first treatment cycle. If you tolerate that dose, your doctor may increase the dose of your other infusions of KYPROLIS. Your doctor will determine the right dose for you.

Discover how Amgen Assist 360™ can help you find resources most important to you.
Call 888-4ASSIST (888-427-7478) Monday through Friday, 9 am to 8 pm Eastern Time.

Talk with your doctor about how much KYPROLIS you will be given and how often you will receive it. Understanding your schedule can help you plan ahead for your KYPROLIS treatment.

If your doctor has prescribed KYPROLIS for you, ask about the KYPROLIS Starter Kit. It has useful tools to help you take an active role in your care. Find resources to help you start treatment.

Discover how Amgen Assist 360™ can help you find resources most important to you.
Call 888-4ASSIST (888-427-7478) Monday through Friday, 9 am to 8 pm Eastern Time.

*Terms in burgundy can be found in the Glossary.

^Back to top

IMPORTANT SAFETY INFORMATION AND APPROVED USES

KYPROLIS® (carfilzomib) can cause serious side effects:
  • Heart problems: KYPROLIS can cause heart problems or worsen pre-existing heart conditions. Death due to cardiac arrest has occurred within one day of KYPROLIS administration. Before starting KYPROLIS, you should have a full medical work-up (including blood pressure and fluid management). You should be closely monitored during treatment.
  • Kidney problems: There have been reports of sudden kidney failure in patients receiving KYPROLIS. Your kidney function should be closely monitored during treatment.
  • Tumor lysis syndrome (TLS): Cases of TLS have been reported in patients receiving KYPROLIS, including fatalities. You should be closely monitored during treatment for any signs of TLS.
  • Lung damage: Cases of lung damage have been reported in patients receiving KYPROLIS, including fatal cases.
  • Pulmonary hypertension (high blood pressure in the lungs): There have been reports of pulmonary hypertension in patients receiving KYPROLIS.
  • Lung complications: Shortness of breath was reported in patients receiving KYPROLIS. Your lung function should be closely monitored during treatment.
  • High blood pressure: Cases of high blood pressure, including fatal cases, have been reported in patients receiving KYPROLIS. Your blood pressure should be closely monitored during treatment.
  • Blood clots: There have been reports of blood clots in patients receiving KYPROLIS. If you are at high risk for blood clots, your doctor can recommend ways to lower the risk.
  • If you are using KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone, your doctor should assess and may prescribe another medicine to help lower your risk for blood clots.
  • If you are using birth control pills or other medical forms of birth control associated with a risk of blood clots, talk to your doctor and consider a different method of birth control during treatment with KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone.
  • Infusion reactions: Symptoms of infusion reactions included fever, chills, joint pain, muscle pain, facial flushing and/or swelling, vomiting, weakness, shortness of breath, low blood pressure, fainting, chest tightness, and chest pain. These symptoms can occur immediately following infusion or up to 24 hours after administration of KYPROLIS. If you experience any of these symptoms, contact your doctor immediately.
  • Severe bleeding problems: Fatal or serious cases of bleeding problems have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms of blood loss.
  • Very low platelet count: Low platelet levels can cause unusual bruising and bleeding. You should have regular blood tests to check your platelet count during treatment.
  • Liver problems: Cases of liver failure, including fatal cases, have been reported in patients receiving KYPROLIS. Your liver function should be closely monitored during treatment.
  • Blood problems: Cases of a blood disease called thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal cases, have been reported in patients who received KYPROLIS. Your doctor should monitor your signs and symptoms.
  • Brain problems: A nerve disease called Posterior Reversible Encephalopathy Syndrome (PRES), formerly called Reversible Posterior Leukoencephalopathy Syndrome (RPLS), has been reported in patients receiving KYPROLIS. It can cause seizure, headache, lack of energy, confusion, blindness, altered consciousness, and other visual and nerve disturbances, along with high blood pressure. Your doctor should monitor your signs and symptoms.
  • Possible fetal harm: KYPROLIS can cause harm to a fetus (unborn baby) when given to a pregnant woman. Women should avoid becoming pregnant during treatment with KYPROLIS. Men should avoid fathering a child during treatment with KYPROLIS. KYPROLIS can cause harm to a fetus if used during pregnancy or if you or your partner become pregnant during treatment with KYPROLIS.
You should contact your doctor immediately if you experience any of the following:
  • Shortness of breath
  • Prolonged, unusual or excessive bleeding
  • Yellowing of the skin and/or eyes (jaundice)
  • Headaches, confusion, seizures, or loss of sight
  • Pregnancy (women should not receive KYPROLIS if they are pregnant or breastfeeding)
  • Any other side effect that bothers you or does not go away
What are the possible side effects of KYPROLIS?
  • The most common side effects occurring in at least 20% of patients receiving KYPROLIS in the combination therapy trials are: low red blood cell count, low white blood cell count, diarrhea, difficulty breathing, tiredness (fatigue), low platelets, fever, sleeplessness (insomnia), muscle spasm, cough, upper airway (respiratory tract) infection, and decreased potassium levels.
  • The most common side effects occurring in at least 20% of patients receiving KYPROLIS when used alone (monotherapy) in trials are: low red blood cell count, tiredness (fatigue), low platelets, nausea, fever, difficulty breathing, diarrhea, headache, cough, swelling of the lower legs or hands.

These are not all the possible side effects of KYPROLIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please talk to your doctor and see the full Product Information for additional information.

APPROVED USES

  • KYPROLIS® (carfilzomib) is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat multiple myeloma.
  • KYPROLIS® (carfilzomib) is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one or more previous treatments for multiple myeloma. KYPROLIS is approved for use alone to treat relapsed or refractory multiple myeloma.